A Phase 3 interventional study of Filgotinib and Placebo in Crohn's Disease, sponsored by Galapagos NV. Terminated at 487 sites in 40 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-10.
Sponsored by Galapagos NV · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.
Among the 660 studies in Crohn Disease with a site in United States, this one is the 13th largest by enrollment of the 528 interventional ones that give a count, is one of 37 that started in 2017, is one of 124 in phase 3, and was the 326th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:
Shattuck Labs, Inc. · Sites in United States
Ages 18–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
Agomab Spain S.L.U. · Sites in United States, Serbia, United Kingdom
Ages 18+
University of Miami · Sites in United States
Ages 16–75
The Cleveland Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
660 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 179 · Phase 3 134 · Phase 4 41
First in 1995; this study’s year is marked. 37 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,188 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 60 across the 528 interventional studies, 168 across the 128 observational. Of the 452 that completed or were terminated, 205 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
310 of 660 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 3 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
59 of the studies in Crohn Disease with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT05660746Phase 3Children's Hospital Medical Center, CincinnatiPrecise Infliximab Exposure and Pharmacodynamic Control | 2027-03-31 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
Add all 59 to your calendar (.ics) → With an account.
Among the 660 studies in Crohn Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in Crohn's disease (CD).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received filgotinib 200 milligrams (mg) blinded and completed the parent study, continued to receive filgotinib 200 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 200 mg. Participants who exited the parent study due to disease worsening or failure to meet response or remission criteria, with the exception of US and Korean males who were not considered dual-biologic refractory, received filgotinib 200 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).
Drug: Filgotinib
Participants who received filgotinib 100 mg blinded and completed the parent study, continued to receive filgotinib 100 mg blinded in this study. After unblinding of the parent study, participants continued open-label on filgotinib 100 mg. Male participants from the US \& Korea who were not considered dual biologic refractory, and who exited the parent study due to disease worsening or failure to meet response or remission criteria, received filgotinib 100 mg open-label in this study. Treatment was administered orally once a day until filgotinib becomes commercially available or until the early termination (up to 308 weeks).
Drug: Filgotinib
Participants who received placebo and completed the parent study, continued to receive placebo in this extension study. After unblinding of the parent study, participants on placebo treatment discontinued study drug and study participation. Treatment was administered orally once a day until unblinding of the parent study (up to 308 weeks).
Drug: Placebo
Tablet administered orally once a day
Also known as: GS-6034, GLPG0634, Jyseleca®
Tablet administered orally once a day
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug.
Time frame: From the First Dose to Week 312
Change From Baseline in Patient Reported Outcomes 2 (PRO2) Scores for Liquid or Very Soft Stools
The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of liquid or very soft stools were summed over the 7 days prior to each visit. The remaining predictors were also weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline for number of liquid or very soft stool per day was reported.
Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Change From Baseline in Patient Reported Outcomes (PRO2) Scores for Abdominal Pain
The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline in abdominal pain was reported.
Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Change From Baseline in CDAI Scores
The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.
Time frame: Baseline, Week 12, Week 24, Week 48, Week 96, Week 156, Week 216, Week 264, and Week 300
Participants were enrolled at study sites in 37 countries: Australia, Austria, Belgium, Canada, Croatia, Czech Republic, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, the Netherlands, New-Zealand, Poland, Portugal, Republic of Korea, Romania, Russia, Serbia, Singapore, Slovakia, South-Africa, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Ukraine, the United Kingdom, and the United States (US).
| Milestone | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Started | 945 | 119 | 124 |
| Treated | 944 | 119 | 124 |
| Completed | 0 | 0 | 0 |
| Not completed | 945 | 119 | 124 |
| Withdrew: Adverse event | 298 | 35 | 25 |
| Withdrew: Sponsors decision | 287 | 41 | 12 |
| Withdrew: Withdrawal by subject | 158 | 20 | 18 |
| Withdrew: Investigators discretion | 169 | 14 | 13 |
| Withdrew: Lost to follow-up | 10 | 4 | 0 |
| Withdrew: Pregnancy | 8 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 3 | 0 |
| Withdrew: Non-compliance with study drug | 6 | 1 | 0 |
| Withdrew: Death | 3 | 1 | 1 |
| Withdrew: Current study unblinded and participant confirmed on placebo | 0 | 0 | 55 |
| Withdrew: Enrolled but not treated | 1 | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant administered a study drug, and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug whether or not considered related to the study drug. Treatment-emergent adverse events (TEAEs) were defined as 1 or both of the following: * Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug.
| Participants | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 820 | 103 | 96 |
The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of liquid or very soft stools were summed over the 7 days prior to each visit. The remaining predictors were also weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline for number of liquid or very soft stool per day was reported.
| Number of liquid/very soft stools/day | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Baseline | 5.6 ± 3.26 | 4.0 ± 3.12 | 2.2 ± 1.92 |
| Change at Week 12 | -1.6 ± 2.71 | -0.7 ± 2.01 | 0.2 ± 1.44 |
| Change at Week 24 | -1.8 ± 2.89 | -0.7 ± 2.59 | 0.1 ± 1.15 |
| Change at Week 48 | -2.0 ± 3.14 | -0.8 ± 2.49 | 0.0 ± 1.21 |
| Change at Week 96 | -2.2 ± 3.11 | -0.7 ± 2.70 | 0.4 ± 2.79 |
| Change at Week 156 | -2.4 ± 3.14 | -0.7 ± 3.19 | -0.2 ± 1.63 |
| Change at Week 216 | -2.8 ± 3.17 | -1.2 ± 4.10 | 1.0 ± 1.41 |
| Change at Week 264 | -2.0 ± 2.86 | -4.8 ± 6.18 | — |
| Change at Week 300 | 0.0 ± 2.71 | — | — |
The PRO2 was a composite score based on 2 components of CDAI, the number of liquid or soft stools/day for 7 days, stool frequency and abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain) assessed for 7 days. The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (0-3), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome. Change from baseline in abdominal pain was reported.
| units on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Baseline | 1.6 ± 0.91 | 1.0 ± 0.89 | 0.7 ± 0.75 |
| Change at Week 12 | -0.6 ± 0.91 | -0.2 ± 0.65 | 0.0 ± 0.52 |
| Change at Week 24 | -0.7 ± 0.92 | -0.2 ± 0.75 | 0.0 ± 0.51 |
| Change at Week 48 | -0.8 ± 0.97 | -0.3 ± 0.70 | -0.1 ± 0.54 |
| Change at Week 96 | -0.8 ± 1.00 | -0.2 ± 0.73 | 0.0 ± 0.55 |
| Change at Week 156 | -0.8 ± 0.98 | -0.2 ± 0.77 | 0.0 ± 0.57 |
| Change at Week 216 | -0.9 ± 1.05 | -0.5 ± 0.88 | 0.0 ± 0.00 |
| Change at Week 264 | -0.8 ± 0.64 | -1.3 ± 0.50 | — |
| Change at Week 300 | -0.3 ± 0.50 | — | — |
The CDAI system was a composite index of 8 disease activity variables: severity of abdominal pain, general well-being, very soft/liquid stool frequency, extra-intestinal symptoms, need for antidiarrheal drugs, presence of an abdominal mass, body weight and hematocrit. Participants reported information regarding symptoms using a diary. The sub scores of abdominal pain (rated on a scale of 0-3, higher values mean greater abdominal pain), general well-being (0-4, higher values mean worse well-being), and number of very soft or liquid stools were then summed over the 7 days prior to each visit. Additionally, the remaining predictors were also noted and weighted to create the total CDAI score which ranged from 0-600 with a higher score indicating a worse outcome.
| units on a scale | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Baseline | 280.5 ± 116.58 | 189.9 ± 112.73 | 120.4 ± 81.33 |
| Change at Week 12 | -86.8 ± 114.02 | -29.1 ± 79.84 | 4.2 ± 53.42 |
| Change at Week 24 | -98.5 ± 122.68 | -30.8 ± 92.92 | 5.7 ± 51.30 |
| Change at Week 48 | -110.2 ± 125.08 | -40.9 ± 91.47 | 0.6 ± 49.32 |
| Change at Week 96 | -118.6 ± 131.49 | -23.3 ± 91.94 | 11.0 ± 69.29 |
| Change at Week 156 | -121.4 ± 132.33 | -33.5 ± 99.15 | 0.3 ± 59.27 |
| Change at Week 216 | -137.0 ± 147.14 | -57.5 ± 121.12 | 2.5 ± 37.76 |
| Change at Week 264 | -134.8 ± 128.86 | -171.5 ± 141.81 | — |
| Change at Week 300 | -32.5 ± 92.99 | — | — |
Collected over From the First Dose to Week 312. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Filgotinib 200 mg | 6/944 (0.6%) | 284/944 (30.1%) | 697/944 (73.8%) |
| Filgotinib 100 mg | 2/119 (1.7%) | 34/119 (28.6%) | 89/119 (74.8%) |
| Placebo | 1/124 (0.8%) | 20/124 (16.1%) | 78/124 (62.9%) |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 101/944 | 5/119 | 4/124 |
| Small intestinal obstructionGastrointestinal disorders | 11/944 | 9/119 | 3/124 |
| Abdominal painGastrointestinal disorders | 17/944 | 2/119 | 0/124 |
| Intestinal obstructionGastrointestinal disorders | 8/944 | 2/119 | 0/124 |
| Anal abscessInfections and infestations | 15/944 | 0/119 | 0/124 |
| Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/944 | 1/119 | 0/124 |
| Papillary renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/944 | 1/119 | 0/124 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/944 | 1/119 | 0/124 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/944 | 1/119 | 0/124 |
| Condition aggravatedGeneral disorders | 0/944 | 1/119 | 0/124 |
| Event | Filgotinib 200 mg | Filgotinib 100 mg | Placebo |
|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 210/944 | 26/119 | 20/124 |
| COVID-19Infections and infestations | 127/944 | 17/119 | 9/124 |
| Abdominal painGastrointestinal disorders | 93/944 | 15/119 | 15/124 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 82/944 | 15/119 | 1/124 |
| NasopharyngitisInfections and infestations | 81/944 | 13/119 | 6/124 |
| HeadacheNervous system disorders | 79/944 | 4/119 | 11/124 |
| DiarrhoeaGastrointestinal disorders | 54/944 | 10/119 | 11/124 |
| NauseaGastrointestinal disorders | 74/944 | 8/119 | 4/124 |
| VomitingGastrointestinal disorders | 67/944 | 3/119 | 3/124 |
| PyrexiaGeneral disorders | 65/944 | 3/119 | 0/124 |
Safety analysis set included all participants who took at least 1 dose of study drug in this study.
| Age, Continuous(years) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 39 ± 13.60 | 47 ± 13.28 | 42 ± 12.42 | 40 ± 13.6 |
| Sex: Female, Male(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 514 | 33 | 56 | 603 |
| Male | 430 | 86 | 68 | 584 |
| Ethnicity (NIH/OMB)(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 18 | 5 | 0 | 23 |
| Not Hispanic or Latino | 904 | 112 | 123 | 1139 |
| Unknown or Not Reported | 22 | 2 | 1 | 25 |
| Race (NIH/OMB)(Participants) | Filgotinib 200 mg | Filgotinib 100 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 137 | 18 | 23 | 178 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 2 |
| Black or African American | 18 | 10 | 3 | 31 |
| White | 739 | 89 | 96 | 924 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 47 | 2 | 2 | 51 |
Showing the first 100 of 487 sites across 40 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Aug 2023, 76 months.
Results were first posted in Jul 2024, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634